BRCA1 and cancer: BRCA1 overexpression significantly increased the IC50 index for doxorubicin, paclitaxel, and cisplatin compared with MCF-7-LXSN cells, indicating that BRCA1 promotes the sensitivity of MCF-7 cells to anti-cancer treatment (Fig. 4).